Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Metrics to compare | TVGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipTVGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −44.0x | −3.2x | −0.6x | |
PEG Ratio | −0.43 | 0.01 | 0.00 | |
Price/Book | −15.2x | 0.2x | 2.6x | |
Price / LTM Sales | - | 2,179.0x | 3.2x | |
Upside (Analyst Target) | 288.9% | 114.0% | 44.6% | |
Fair Value Upside | Unlock | −6.3% | 7.3% | Unlock |